BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...

Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

TRILUMINATE's primary endpoint was a hierarchical composite of death from any cause or tricuspid valve surgery, ...

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Abbott (NYSE: ABT) today announced data demonstrating substantial, sustained improvements with its TriClip system.